+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Viberzi"

Irritable Bowel Syndrome Treatment Market Size, Share & Analysis Report by Type (IBS-C, IBS-D), Product (Xifaxan, Linzess/Constella, Viberzi, Amitiza), Distribution Channel, Region, and Segment Forecasts, 2025-2030 - Product Thumbnail Image

Irritable Bowel Syndrome Treatment Market Size, Share & Analysis Report by Type (IBS-C, IBS-D), Product (Xifaxan, Linzess/Constella, Viberzi, Amitiza), Distribution Channel, Region, and Segment Forecasts, 2025-2030

  • Report
  • October 2024
  • 100 Pages
  • Global
From
Irritable Bowel Syndrome (IBS) Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Irritable Bowel Syndrome (IBS) Therapeutics - Global Strategic Business Report

  • Report
  • April 2025
  • 269 Pages
  • Global
From
Irritable Bowel Syndrome Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2023 to 2031 - Product Thumbnail Image

Irritable Bowel Syndrome Treatment Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2023 to 2031

  • Report
  • December 2023
  • 116 Pages
  • Global
From
Irritable Bowel Syndrome with Diarrhea Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030 - Product Thumbnail Image

Irritable Bowel Syndrome with Diarrhea Market Size, Market Share, Application Analysis, Regional Outlook, Growth Trends, Key Players, Competitive Strategies and Forecasts, 2022 to 2030

  • Report
  • August 2022
  • 120 Pages
  • Global
From
  • 4 Results (Page 1 of 1)
Loading Indicator

Viberzi is a prescription medication used to treat irritable bowel syndrome with diarrhea (IBS-D) in adults. It is a type of gastrointestinal drug, which is a class of medications used to treat digestive disorders. Viberzi works by blocking certain receptors in the gut that cause pain and diarrhea. It is taken orally, usually once a day. Viberzi is a relatively new drug, having been approved by the U.S. Food and Drug Administration (FDA) in 2015. It is manufactured by Allergan, a global pharmaceutical company. Other companies in the gastrointestinal drug market include AbbVie, AstraZeneca, and Takeda Pharmaceuticals. Show Less Read more